Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CNTX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Extended-release Onapristone | Refractory Endometrial Adenocarcinoma | Phase 2 · NCT04719273 | Completed |
| Onapristone | Breast Cancer | Phase 1/2 · NCT05618613 | Terminated |
| Onapristone ER | Granulosa Cell Ovarian Cancer | Phase 2 · NCT03909152 | Completed |
| CT-202 | Triple Negative Breast Cancer (TNBC) | Phase 1 · NCT07545122 | Recruiting |
| Anti-mesothelin T-cell Engaging Bispecif | Mesothelin-Expressing Tumors | Phase 1 · NCT06756035 | Recruiting |
| Anti-CLDN6/CD3 Bispecific Antibody CTIM- | Platinum-resistant Ovarian Cancer | Phase 1 · NCT06515613 | Recruiting |
Also used in these trials (approved or third-party drugs, not CNTX's own candidates): Anastrozole, Elacestrant, Fulvestrant, Letrozole, Palbociclib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CNTX holds $43M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.2M/quarter from operations, an estimated runway of 14 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 43 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CNTX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CNTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →